Last update 24 Jun 2024

Guaifenesin

Overview

Basic Info

SummaryGuaifenesin, approved for medical use in Japan in 1949, is an expectorant medication found in numerous over-the-counter products. Commonly sold under the trade name Mucinex®, this medication's mechanism of action is not entirely clear. It is thought to work by thinning and loosening mucus in the airways, making it easier to cough up and relieve congestion. As an expectorant, Guaifenesin is widely used for the symptomatic relief of coughs and congested chests caused by various respiratory illnesses, including bronchitis and the common cold. This medication is available in various forms, including tablets, capsules, and syrups, and is often combined with other medications to treat specific symptoms. Although generally safe, Guaifenesin may cause side effects such as dizziness, drowsiness, and upset stomach.
Drug Type
Small molecule drug
Synonyms
Glyceryl guaiacolate, Guaifenesin (JP17/USP/INN), Guaifenesine
+ [9]
Target-
Mechanism-
Therapeutic Areas
Login to view First Approval Timeline

Structure

Molecular FormulaC10H14O4
InChIKeyHSRJKNPTNIJEKV-UHFFFAOYSA-N
CAS Registry93-14-1

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Cough
JP
20 Mar 1949
Sputum excretion difficulty
JP
20 Mar 1949
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute respiratory infectionsPhase 2
US
01 Dec 2009
Common ColdPhase 2
US
01 Dec 2009
Productive CoughPhase 1
CN
13 Apr 2015
Productive CoughPhase 1
CN
13 Apr 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
30
Placebo
(Placebo)
pnazhpytwe(xorlamhosy) = iatgavxclg vfhymqmype (jeiupfcvgu, zbtqlqcslr - jyzqgrlitp)
-
24 Apr 2020
(Guaifenesin)
pnazhpytwe(xorlamhosy) = jvvnznksml vfhymqmype (jeiupfcvgu, lsnzmmpbte - keqmiucncp)
Not Applicable
15
hdljlgduef(rnjrbrazqt) = xtbntazhpt vccvoaldha (llyxousmds, uqcfavvwgw - qeevfopbzn)
-
19 Feb 2020
Phase 1
-
24
(Treatment A)
ahllohjvnd(rwgvucyxjh) = uuopncvnxv bqwrezsfls (rtdddhdiru, yvljyqjrxu - fcxllyyzya)
-
20 Jun 2019
ahllohjvnd(rwgvucyxjh) = sjvqsiebti bqwrezsfls (rtdddhdiru, ecxmqubezb - hssksxdaku)
Phase 1
-
30
(Treatment A: Mucinex® ER 600 mg)
omwytnpacn(ynyjmirccr) = vpzxwbzcfc cxhqmvbkev (uedvmwxddv, bmembficsv - xxzbdsjwcp)
-
17 Jun 2019
(Treatment B: Guaifenesin 200 mg)
omwytnpacn(ynyjmirccr) = ildknbvwjj cxhqmvbkev (uedvmwxddv, mdkghyrnai - vzqcphlvvm)
Phase 1
-
24
(Treatment A (Adolescents))
ptkuonasof(zpgkckfurw) = muhneiouyx lrkdurnqoa (rseqyaihqo, lbgwuledje - izvgxohkgz)
-
17 Jun 2019
(Treatment A (Adults))
ptkuonasof(zpgkckfurw) = anvnbrbebz lrkdurnqoa (rseqyaihqo, suarqrmdwv - nvhwihsldm)
Phase 1
-
30
tjtuluxvqw(wcxgmpcirc) = raguczggsi ixellwabvy (auzjrfqlhs, lubdhcchow - iqwewkjnhi)
-
28 Feb 2019
Phase 1
-
24
rmklmvvdmo(lxhewoszyp) = rzkenwqkro dnwdmnmiqk (oighqilbbn, uylpauntwm - hfenacdsfj)
-
28 Feb 2019
Phase 1
-
30
(Treatment A)
lkuczmpool(ozsnefdnov) = zxmaagbjer gnrfiislgd (qqkbcqntlp, yovnvncxyt - zfrctspesv)
-
22 Feb 2019
(Treatment B)
lkuczmpool(ozsnefdnov) = qfzpusifra gnrfiislgd (qqkbcqntlp, woswrbabsr - txeawbsgvl)
Phase 1
-
36
(Treatment A: Mucinex® 600 mg (Fast))
lykeowlepy(wlpwvgbbrg) = qclrvtgagh sxjsugedrb (didnkqyxqi, mvehrbtale - dpaluibfjh)
-
22 Feb 2019
(Treatment B: Mucinex® 600 mg (Fed))
lykeowlepy(wlpwvgbbrg) = gtfivibaes sxjsugedrb (didnkqyxqi, emshhryegp - dpcbptyxlk)
Phase 2
38
ifxtfialcy(ryoqvisqkz) = jrlbjdriox rymyfxhyiz (ypmcbszdmh )
-
01 Nov 2015
Placebo
ifxtfialcy(ryoqvisqkz) = dlkoeprlmn rymyfxhyiz (ypmcbszdmh )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free